OpenAI Launches cderGPT to Accelerate Drug Evaluation

OpenAI is developing a mysterious project called ​​cderGPT​​, aimed at leveraging artificial intelligence to accelerate the drug evaluation process. The initiative has drawn attention from the U.S. Food and Drug Administration (FDA), with which it has held multiple discussions. FDA Commissioner Marty Makary noted that the lengthy timeline for drug approvals urgently needs modernization, and AI has the potential to improve the current situation. While the FDA’s review process currently takes about a year, AI technology could potentially shorten certain stages of this timeline. However, the industry also expresses concerns about the reliability of AI in the review process, emphasizing the need for careful evaluation of the training data and application outcomes of AI models. Overall, while ​​cderGPT​​ may bring transformative changes to drug evaluation, it still faces dual challenges in technology and ethics.